Nesiritide vs Terlipressin
Research Verdict
Terlipressin is the stronger research reference for the stated comparison criteria. Nesiritide (Natrecor): ASCEND-HF (n=7,141) showed no benefit on dyspnea or mortality vs.
Quick Answers
Which is better, Nesiritide or Terlipressin?
Terlipressin is the stronger research reference for the stated comparison criteria. Nesiritide (Natrecor): ASCEND-HF (n=7,141) showed no benefit on dyspnea or mortality vs.
What is the key difference between Nesiritide and Terlipressin?
Nesiritide is a recombinant BNP with vasodilatory effects in heart failure that proved clinically futile; terlipressin is a vasopressin analog with splanchnic vasoconstriction for hepatorenal syndrome - completely different targets and outcomes.
Evidence Comparison
Nesiritide (Natrecor): ASCEND-HF (n=7,141) showed no benefit on dyspnea or mortality vs. placebo - effectively a negative trial that ended its clinical utility. Terlipressin (Terlivaz): CONFIRM trial (n=300) met its primary endpoint for hepatorenal syndrome type 1 reversal; FDA approved 2022 with REMS due to respiratory failure risk. Terlipressin has the positive outcomes evidence.
Evidence Context Favoring Nesiritide
No current evidence-based scenario favors nesiritide - ASCEND-HF effectively ended its clinical role.
Evidence Context Favoring Terlipressin
Hepatorenal syndrome type 1 reversal where CONFIRM trial evidence applies, with awareness of REMS requirements for respiratory monitoring.
Side-by-Side Snapshot
| Evidence grade | Nesiritide: Level A Terlipressin: Level A |
|---|---|
| Research status | Nesiritide: FDA Approved Terlipressin: FDA Approved |
| Primary category | Nesiritide: Healing & Recovery Terlipressin: Healing & Recovery |
| Cited studies | Nesiritide: 3 Terlipressin: 3 |